Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2008, for Spatializer Audio Laboratories, Inc. (Note: The input metadata referenced "Enveric Biosciences," but the filing text explicitly identifies the registrant as Spatializer Audio Laboratories, Inc.). The Company is a shell entity following the sale of substantially all its operating assets and intellectual property to a subsidiary of DTS, Inc. on July 2, 2007. Commercial operations ceased in 2006, and the Company currently has no revenue-generating business model.
Key Financial Metrics
| Metric | Q3 2008 | Q3 2007 | 9 Months 2008 | 9 Months 2007 |
|---|---|---|---|---|
| Revenues | $0 | $30,107 | $0 | $750,706 |
| Net Income (Loss) | $(7,747) | $472,342 | $(108,621) | $855,768 |
| Operating Expenses | $7,747 | $88,868 | $116,428 | $369,178 |
| Cash and Equivalents (End of Period) | $87,342 | $613,758 | $87,342 | $613,758 |
| Working Capital | $83,484 | $1,557,105 | $83,484 | $1,557,105 |
| Debt (Notes Payable) | $9,680 | $0 | $9,680 | $0 |
Liquidity: Cash decreased significantly from $582,019 at year-end 2007 to $87,342 at September 30, 2008. This reduction was primarily due to a $1,365,000 cash distribution to shareholders in April 2008 and the liquidation of $1,000,000 in short-term investments to fund that distribution.
Material Changes vs. Prior Period
- Revenue Elimination: Royalty revenues dropped to $0 for the quarter and nine months ended September 30, 2008, compared to $30,107 and $750,706 in the prior year periods, respectively. This reflects the complete cessation of licensing operations following the asset sale in July 2007.
- Profitability Shift: The Company reported a net loss of $7,747 for Q3 2008, contrasting with a net gain of $472,342 in Q3 2007. The prior year gain was largely driven by a one-time gain on the sale of assets ($515,077), which did not recur in 2008.
- Expense Reduction: Operating expenses decreased to $7,747 in Q3 2008 from $88,868 in Q3 2007, reflecting the wind-down of administrative activities and the suspension of R&D and sales functions.
- Capital Structure: A new investor group took control of the Company in April 2008 following a change in control transaction. The Board was reconstituted with Jay A. Gottlieb as Chairman.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that the Company's circumstances, including significant operating losses and lack of revenue, raise substantial doubt about its ability to continue as a going concern. The financial statements do not include adjustments that might result from this uncertainty.
- Future Operations: There is no current source of future cash flow. Management states that maintaining liquidity requires a new business model and outside funding. While new investors may propose a new direction, there is no assurance of success.
- Internal Controls: The Company identified a material weakness in internal controls due to limited segregation of duties, as only one part-time employee and a contract bookkeeper remained to manage accounting records.
- Subsequent Event: A 1-for-10 reverse stock split was announced to become effective on November 21, 2008.
- Tax Assets: Net operating loss carryforwards of approximately $26 million are expected to be unusable due to the change in control.
Investor Verification Checklist
- Company Identity: Verify that the filing pertains to Spatializer Audio Laboratories, Inc., not Enveric Biosciences (metadata discrepancy).
- Going Concern Status: Confirm the Company's ability to fund operations without a new business plan or capital raise.
- Reverse Split Impact: Assess the implications of the 1-for-10 reverse stock split effective November 2008 on share liquidity and price.
- Management Plan: Investigate any new business initiatives proposed by the new investor group (Gottlieb, Schneider, Pearce) to generate revenue.
- Internal Control Weaknesses: Review the adequacy of financial reporting given the material weakness in segregation of duties.